Neurology 2001;57:1248-1252
© 2001 American Academy of Neurology
Articles
Axonal loss in normal-appearing white matter in a patient with acute MS
C. Bjartmar, MD PhD;,
R. P. Kinkel, MD,
G. Kidd, PhD,
R. A. Rudick, MD and
B. D. Trapp, PhD
From the Department of Neurosciences, Lerner Research Institute (Drs. Bjartmar, Kidd, Rudick, and Trapp), Department of Neurology (Mellen Center) (Drs. Kinkel and Rudick), and the Center for Clinical Research (Dr. Rudick), Cleveland Clinic Foundation, OH.
Address correspondence and reprint requests to Dr. Bruce D. Trapp, Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: trappb{at}ccf.org
Background: Brain imaging studies detect abnormalities in normal-appearing white matter in patients with MS. Objective: To investigate the histopathologic basis for these changes in autopsy tissue from a patient with MS with 9 months’ disease duration and a terminal brain stem lesion. Methods: The brain stem and spinal cord were analyzed ultrastructurally and immunocytochemically for axons, myelin, and activated microglia/macrophages. Results: Pathologic findings were consistent with a terminal inflammatory demyelinated lesion at the cervicomedullary junction. The ventral spinal cord column, containing descending tracts, exhibited 22% axonal loss at segment C7, but grossly normal immunostaining for myelin. Confocal and electron microscopy revealed myelin sheaths without axonal content and initial stages of myelin degradation by activated microglia/macrophages among intact myelinated axons. Axonal number and appearance was normal in ascending sensory tracts. Conclusions: These studies confirm axonal degeneration in the absence of myelin loss as one histopathologic correlate to abnormal MR findings in patients with MS.
This article has been cited by other articles:
|
|
|
|
 
M. Inglese, G. Madelin, N. Oesingmann, J. S. Babb, W. Wu, B. Stoeckel, J. Herbert, and G. Johnson
Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla
Brain,
January 27, 2010;
(2010):
awp334v1 - awp334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I I Kirov, V Patil, J S Babb, H Rusinek, J Herbert, and O Gonen
MR spectroscopy indicates diffuse multiple sclerosis activity during remission
J. Neurol. Neurosurg. Psychiatry,
December 1, 2009;
80(12):
1330 - 1336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Soulika, E. Lee, E. McCauley, L. Miers, P. Bannerman, and D. Pleasure
Initiation and Progression of Axonopathy in Experimental Autoimmune Encephalomyelitis
J. Neurosci.,
November 25, 2009;
29(47):
14965 - 14979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Amadio, C. Montilli, R. Magliozzi, G. Bernardi, R. Reynolds, and C. Volonte
P2Y12 Receptor Protein in Cortical Gray Matter Lesions in Multiple Sclerosis
Cereb Cortex,
September 26, 2009;
(2009)
bhp193v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Podbielska and E. Hogan
Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?
Multiple Sclerosis,
September 1, 2009;
15(9):
1011 - 1029.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Das Sarma, L. C. Kenyon, S. T. Hingley, and K. S. Shindler
Mechanisms of Primary Axonal Damage in a Viral Model of Multiple Sclerosis
J. Neurosci.,
August 19, 2009;
29(33):
10272 - 10280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Furby, T Hayton, D Altmann, R Brenner, J Chataway, K. Smith, D. Miller, and R Kapoor
Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis
Multiple Sclerosis,
June 1, 2009;
15(6):
687 - 694.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G Tedeschi, D Dinacci, M Comerci, L Lavorgna, G Savettieri, A Quattrone, P Livrea, F Patti, V Brescia Morra, G Servillo, et al.
Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study
Multiple Sclerosis,
February 1, 2009;
15(2):
204 - 211.
[Abstract]
[PDF]
|
|
|
|
|
|
|
X. Qi, L. Sun, A. S. Lewin, W. W. Hauswirth, and J. Guy
Long-term Suppression of Neurodegeneration in Chronic Experimental Optic Neuritis: Antioxidant Gene Therapy
Invest. Ophthalmol. Vis. Sci.,
December 1, 2007;
48(12):
5360 - 5370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Cheng, M. Laron, J. S. Schiffman, R. A. Tang, and L. J. Frishman
The Relationship between Visual Field and Retinal Nerve Fiber Layer Measurements in Patients with Multiple Sclerosis
Invest. Ophthalmol. Vis. Sci.,
December 1, 2007;
48(12):
5798 - 5805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rasmussen, Y. Wang, P. Kivisakk, R. T. Bronson, M. Meyer, J. Imitola, and S. J. Khoury
Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing remitting experimental autoimmune encephalomyelitis
Brain,
November 1, 2007;
130(11):
2816 - 2829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tsunoda, T. Tanaka, Y. Saijoh, and R. S. Fujinami
Targeting Inflammatory Demyelinating Lesions to Sites of Wallerian Degeneration
Am. J. Pathol.,
November 1, 2007;
171(5):
1563 - 1575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan, F. Fezza, V. De Chiara, L. Battistini, G. Bernardi, S. Bernardini, et al.
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis
Brain,
October 1, 2007;
130(10):
2543 - 2553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.C. Gustafsson, O. Dahlqvist, J. Jaworski, P. Lundberg, and A.-M.E. Landtblom
Low Choline Concentrations in Normal-Appearing White Matter of Patients with Multiple Sclerosis and Normal MR Imaging Brain Scans
AJNR Am. J. Neuroradiol.,
August 1, 2007;
28(7):
1306 - 1312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dutta and B. D. Trapp
Pathogenesis of axonal and neuronal damage in multiple sclerosis
Neurology,
May 29, 2007;
68(22_suppl_3):
S22 - S31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Inglese, S.-J. Park, G. Johnson, J. S. Babb, L. Miles, H. Jaggi, J. Herbert, and R. I. Grossman
Deep Gray Matter Perfusion in Multiple Sclerosis: Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging at 3 T
Arch Neurol,
February 1, 2007;
64(2):
196 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J H Simon
Brain atrophy in multiple sclerosis: what we know and would like to know
Multiple Sclerosis,
November 1, 2006;
12(6):
679 - 687.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C L Martin, B A Phillips, T J Kilpatrick, H Butzkueven, N Tubridy, E McDonald, and M P Galea
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability
Multiple Sclerosis,
September 1, 2006;
12(5):
620 - 628.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. C. DeLuca, K. Williams, N. Evangelou, G. C. Ebers, and M. M. Esiri
The contribution of demyelination to axonal loss in multiple sclerosis
Brain,
June 1, 2006;
129(6):
1507 - 1516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Wang, R. Allie, K. Conant, N. Haughey, J. Turchan-Chelowo, K. Hahn, A. Rosen, J. Steiner, S. Keswani, M. Jones, et al.
Granzyme B mediates neurotoxicity through a G-protein-coupled receptor
FASEB J,
June 1, 2006;
20(8):
1209 - 1211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kim, A. B. DiBernardo, J. A. Sloane, M. N. Rasband, D. Solomon, B. Kosaras, S. P. Kwak, and T. K. Vartanian
WAVE1 Is Required for Oligodendrocyte Morphogenesis and Normal CNS Myelination
J. Neurosci.,
May 24, 2006;
26(21):
5849 - 5859.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Caramanos, S. Narayanan, and D. L. Arnold
1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review
Brain,
November 1, 2005;
128(11):
2483 - 2506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Petzold, M J Eikelenboom, G Keir, D Grant, R H C Lazeron, C H Polman, B M J Uitdehaag, E J Thompson, and G Giovannoni
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study
J. Neurol. Neurosurg. Psychiatry,
February 1, 2005;
76(2):
206 - 211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Norgren, P. Sundstrom, A. Svenningsson, L. Rosengren, T. Stigbrand, and M. Gunnarsson
Neurofilament and glial fibrillary acidic protein in multiple sclerosis
Neurology,
November 9, 2004;
63(9):
1586 - 1590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D Coombs, A. Best, M. S Brown, D. E Miller, J. Corboy, M. Baier, and J. H Simon
Multiple sclerosis pathology in the normal and abnormal appearing white matter of the corpus callosum by diffusion tensor imaging
Multiple Sclerosis,
August 1, 2004;
10(4):
392 - 397.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Lucchinetti and W. Bruck
The pathology of primary progressive multiple sclerosis
Multiple Sclerosis,
June 1, 2004;
10(1_suppl):
S23 - S30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. M. Dalton, D. T. Chard, G. R. Davies, K. A. Miszkiel, D. R. Altmann, K. Fernando, G. T. Plant, A. J. Thompson, and D. H. Miller
Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes
Brain,
May 1, 2004;
127(5):
1101 - 1107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. DeLuca, G. C. Ebers, and M. M. Esiri
Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts
Brain,
May 1, 2004;
127(5):
1009 - 1018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lucchinetti and W. Bruck
The pathology of primary progressive multiple sclerosis
Multiple Sclerosis,
May 1, 2004;
10(3_suppl):
S23 - S30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Diestel, O. Aktas, D. Hackel, I. Hake, S. Meier, C. S. Raine, R. Nitsch, F. Zipp, and O. Ullrich
Activation of Microglial Poly(ADP-Ribose)-Polymerase-1 by Cholesterol Breakdown Products during Neuroinflammation: a Link between Demyelination and Neuronal Damage
J. Exp. Med.,
December 1, 2003;
198(11):
1729 - 1740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X Lin, C R Tench, B Turner, L D Blumhardt, and C S Constantinescu
Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon {beta}-1a (Rebif) treatment trial
J. Neurol. Neurosurg. Psychiatry,
August 1, 2003;
74(8):
1090 - 1094.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. G. Geurts, G. Wolswijk, L. Bo, P. van der Valk, C. H. Polman, D. Troost, and E. Aronica
Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis
Brain,
August 1, 2003;
126(8):
1755 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Angelov, S. Waibel, O. Guntinas-Lichius, M. Lenzen, W. F. Neiss, T. L. Tomov, E. Yoles, J. Kipnis, H. Schori, A. Reuter, et al.
Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis
PNAS,
April 15, 2003;
100(8):
4790 - 4795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. De Stefano, P. M. Matthews, M. Filippi, F. Agosta, M. De Luca, M. L. Bartolozzi, L. Guidi, A. Ghezzi, E. Montanari, A. Cifelli, et al.
Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability
Neurology,
April 8, 2003;
60(7):
1157 - 1162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tsunoda, L.-Q. Kuang, J. E. Libbey, and R. S. Fujinami
Axonal Injury Heralds Virus-Induced Demyelination
Am. J. Pathol.,
April 1, 2003;
162(4):
1259 - 1269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nicot, P. V. Ratnakar, Y. Ron, C.-C. Chen, and S. Elkabes
Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction
Brain,
February 1, 2003;
126(2):
398 - 412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bergers, J.C.J. Bot, C.J.A. De Groot, C.H. Polman, G.J. Lycklama a Nijeholt, J.A. Castelijns, P. van der Valk, and F. Barkhof
Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions
Neurology,
December 10, 2002;
59(11):
1766 - 1771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Fields and B. Stevens-Graham
NEUROSCIENCE: New Insights into Neuron-Glia Communication
Science,
October 18, 2002;
298(5593):
556 - 562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kuhlmann, G. Lingfeld, A. Bitsch, J. Schuchardt, and W. Bruck
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
Brain,
October 1, 2002;
125(10):
2202 - 2212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Chard, C. M. Griffin, M. A. McLean, P. Kapeller, R. Kapoor, A. J. Thompson, and D. H. Miller
Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis
Brain,
October 1, 2002;
125(10):
2342 - 2352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Petzold, M. J. Eikelenboom, D. Gveric, G. Keir, M. Chapman, R. H. C. Lazeron, M. L. Cuzner, C. H. Polman, B. M. J. Uitdehaag, E. J. Thompson, et al.
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations
Brain,
July 1, 2002;
125(7):
1462 - 1473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
